InvestorsObserver is giving Genmab A/S - ADR (GMAB) an Analyst Rating Rank of 21, meaning GMAB is ranked higher by analysts than 21% of stocks. The average price target for GMAB is $37.757 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating GMAB a Buy today. Find out what this means to you and get the rest of the rankings on GMAB!